Our Co-founder and GM interview on vaccines & vaccines manufacturing across Africa & MEA in one of the top UAE/GCC media platforms.
“The real and greatest challenge in vaccine manufacturing in Egypt and the Middle East is to find a mechanism for the transfer of manufacturing technology and scientific research to vaccines,” said Dr. Nibal Dahaba, CEO of Gennecs Vaccines and Medicines Holding.
“Vaccines have no alternatives, and this is different from regular medicines, which usually have alternatives,” Dahaba said, noting that “the process of manufacturing biological products, the first of which is vaccines, needs the approval of the vaccine owner (originator) to transfer his manufacturing technology, which I consider to be a major reason why there are no vaccine manufacturing and production plants in the Arab world and Africa so far.”
“What we are witnessing in the Middle East right now is mobilizing one or two types of vaccines, and we are seeking to exploit our vaccine expertise, with multinational companies, which we have spent more than a quarter of a century and can transfer this expertise to Egypt and the region”, she said.
“The estimated cost of launching an integrated plant for all vaccines on the compulsory vaccine schedule with some other vaccines, such as influenza, Covid and papillomavirus, is $90 million to $110 million while avoiding live vaccines.”
